Page last updated: 2024-12-09
2-Methylindole-3-acetic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 589107 |
| CHEMBL ID | 312858 |
| CHEBI ID | 182632 |
| SCHEMBL ID | 379103 |
Synonyms (45)
| Synonym |
|---|
| AC-6734 |
| 1912-43-2 |
| CHEMBL312858 |
| EN300-31810 |
| 2-(2-methyl-1h-indol-3-yl)acetic acid |
| CHEBI:182632 |
| AN-666/13378006 |
| (2-methyl-1h-indol-3-yl)acetic acid |
| OPREA1_079937 |
| MLS000039417 |
| smr000036607 |
| 2-methyl-3-indoleacetic acid, 98% |
| 2-methylindole-3-acetic acid |
| M-3960 |
| STK119955 |
| AKOS000113538 |
| A4222 |
| HMS2462J09 |
| 2-methylindole-3-aceticacid |
| BBL012863 |
| 2-(2-methylindol-3-yl)acetic acid |
| 2-methyl-3-indoleacetic acid |
| FT-0613059 |
| FS-2263 |
| (2-methyl-indol-3-yl)-acetic acid |
| (2-methyl-3-indolyl)acetic acid |
| SCHEMBL379103 |
| (2-methyl-1h-indol-3-yl)acetic acid # |
| 1h-indole-3-acetic acid, 2-methyl- |
| Q-102907 |
| mfcd00075006 |
| SR-01000397827-1 |
| sr-01000397827 |
| DTXSID90343337 |
| 2-me-iaa |
| BCP27439 |
| 2-methylindole-3- acetic acid |
| AMY25853 |
| 2-methyl-idole-3-acetic acid |
| qn5 , |
| 2-(2-methyl-1~{h}-indol-3-yl)ethanoic acid |
| CS-W015941 |
| Z335447192 |
| 2-(2-methyl-3-indolyl)acetic acid |
| SY062285 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| indole-3-acetic acids | An indol-3-yl carboxylic acid in which the carboxylic acid specified is acetic acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (11)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.5849 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| BRCA1 | Homo sapiens (human) | Potency | 6.3096 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 10.0000 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3872 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 19.8003 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 1.8356 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| Caspase-7 | Homo sapiens (human) | Potency | 39.8107 | 3.9811 | 18.5856 | 31.6228 | AID889 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (17)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA binding | Caspase-7 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity | Caspase-7 | Homo sapiens (human) |
| protein binding | Caspase-7 | Homo sapiens (human) |
| peptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type peptidase activity | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity involved in apoptotic process | Caspase-7 | Homo sapiens (human) |
| cysteine-type endopeptidase activity involved in execution phase of apoptosis | Caspase-7 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Caspase-7 | Homo sapiens (human) |
| nucleus | Caspase-7 | Homo sapiens (human) |
| cytoplasm | Caspase-7 | Homo sapiens (human) |
| cytosol | Caspase-7 | Homo sapiens (human) |
| nucleus | Caspase-7 | Homo sapiens (human) |
| nucleoplasm | Caspase-7 | Homo sapiens (human) |
| cytosol | Caspase-7 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (17)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID217022 | Cytotoxicity against Chinese hamster lung fibroblasts (V79 cells) was determined by a clonogenic assay (colonies containing >50 cells were counted and surviving fractions (SF) calculated after 2 hr incubation) | 2002 | Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18 | Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy. |
| AID296505 | Octanol-water partition coefficient, log Kow of the compound | 2007 | Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13 | Binding of ring-substituted indole-3-acetic acids to human serum albumin. |
| AID296506 | Binding affinity to human serum albumin | 2007 | Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13 | Binding of ring-substituted indole-3-acetic acids to human serum albumin. |
| AID90866 | Rate constant for oxidation by HRP (horseradish peroxidase) was determined | 2002 | Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18 | Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||